Enhanced Recovery for Cesarean Deliveries in the United States: Perspectives From the Front Lines – Part 2

A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.

Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.

A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.

A recent poll highlights increasing public demand for broader insurance coverage for in vitro fertilization, underscoring persistent barriers faced by millions without access to adequate fertility care.